Pharmaceutical

ASCO24: Akeso’s bispecific vvonescimab faces a rocky road ahead in NSCLC

While commercial uptake may be difficult for ivonescimab, a positive regulatory decision would help validate Akeso's bispecific platform.

Jun 2, 2024 - 04:00
ASCO24: Akeso’s bispecific vvonescimab faces a rocky road ahead in NSCLC
While commercial uptake may be difficult for ivonescimab, a positive regulatory decision would help validate Akeso's bispecific platform.
Read the original article

Tags:

Previous Article

Clinical trials show promise in treating central nervous system lymphoma, breast...

Next Article

Key opinion leaders on unmet needs in amyotrophic lateral sclerosis

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Johnson & Johnson seeks FDA approval for Tremfya for Crohn’s disease

Johnson & Johnson seeks FDA approval for Tremfya for Cr...

Jun 22, 2024

STAT+: FDA’s Califf wants to get the public as excited about life expectancy as cures

STAT+: FDA’s Califf wants to get the public as excited ...

Nov 9, 2023

People with congenital heart disease are living longer — but facing new threat of heart failure

People with congenital heart disease are living longer ...

Dec 1, 2023